Financials
Financial year 2025
ACE PHARMACEUTICALS BELGIUM from Sint-Martens-Latem, company number BE0732788379, closed financial year 2025 with a result of € 231,722 after tax. For that financial year ACE PHARMACEUTICALS BELGIUM recorded a gross margin of € 531,961 and equity of € 410,226. Compared with financial year 2024, the result moved from € 53,543 to € 231,722. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 9, 2026.
€ 410,226
▲ 130% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 231,722
▲ € 178,178 vs 2024
Profit after tax over the fiscal year.
€ 544,276
▲ € 413,395 vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 350,226.
People and assets in 2025
1
Average over the fiscal year, from the social balance sheet.
€ 118,387
▲ 11% vs 2024
€ 118,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 6,510
▼ 41% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 459,241
▼ 15% vs 2024
€ 85,300 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 122,653
▲ 50% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 122,431
▲ 256% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 140,067 | € 150,079 | € 276,044 | € 531,961 | ▲ 93% |
| Profit after taxes | € 16,719 | € 1,631 | € 53,543 | € 231,722 | ▲ € 178,178 |
| Equity | € 123,329 | € 124,960 | € 178,504 | € 410,226 | ▲ 130% |
| Total debts | € 61,084 | € 1,005,999 | € 1,012,203 | € 1,180,966 | ▲ 17% |
| Cash | € 50,402 | € 12,341 | € 130,882 | € 544,276 | ▲ € 413,395 |
| Retained profit | € 63,329 | € 64,960 | € 118,504 | € 350,226 | ▲ 196% |
| Bank debt | € 0 | € 631,428 | € 540,760 | € 459,241 | ▼ 15% |
| Balance sheet total | € 184,413 | € 1,130,959 | € 1,190,707 | € 1,591,191 | ▲ 34% |
| Employees (FTE) | 1 | 1 | 1 | 1 |
Key figures of ACE PHARMACEUTICALS BELGIUM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ACE PHARMACEUTICALS BELGIUM?
What happened at ACE PHARMACEUTICALS BELGIUM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 231,722 (▲ € 178,178 vs 2024). Source: NBB ↗
- New establishment in Braine-le-Château. KBO
- Start of the company according to the CBE. KBO
In short
From € 16,719 profit in 2022 to € 231,722 profit in 2025.
Paid € 117,649 in corporate taxes since 2022.
Best year ever: 2025, with € 231,722 profit.
On average € 532,000 of value added per employee in 2025.
A new publication or filing at ACE PHARMACEUTICALS BELGIUM? We notify you, reason included.
Follow ACE PHARMACEUTICALS BELGIUMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Pharmentum comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
ACE PHARMACEUTICALS BELGIUMBehind ACE PHARMACEUTICALS BELGIUM are Ronald STEENTJES, TLYS SCS, Ronald Feiter CORNELIS and AMBERSTE HOLDING BV. The shares are held by Pharmentum (49%). It owns 51% of PANNOC CHEMIE itself.
Directors
According to the 2025 annual accounts
Ronald STEENTJES
Managing director
Managing director
Also active at: PANNOC CHEMIE, PHARMA CHEMICALS, Pharmentum, Pharma Chemicals France, PHARMA CHEMICALS NEDERLAND
Ronald Feiter CORNELIS
Director
Director
Shareholders
49%
Participations
51%
Establishments
Establishment units
Physical locations of this company
Xavier De Cocklaan 66 box 5
9831 Sint-Martens-Latem
Parc Industriel(W-B) 19
1440 Braine-le-Château
Active since 22 August 2019
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 9 companies are registered at this address.
All companies at this address →IMMO LARCIER
€ 57,173 gross margin · 2025
Mc THREE HOLDINGS
€ 1.5 million revenue · 2022
G Projects
€ -780 gross margin · 2025
CMN
€ -1,681 gross margin · 2025
Syndiggit
€ 21,828 gross margin · 2025
+4 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
METAREGISTRAR, NL
Website info
Features
Security
Network
Details
- Company number
- 0732.788.379
- VAT number
- BE 0732.788.379
- Registered office
- Xavier De Cocklaan 66 bus 5, 9831 Sint-Martens-Latem
- Names & denominations
- ACE PHARMACEUTICALS BELGIUM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 22 August 2019
- Peppol
- Active · Active since 10 Nov 2025
- Contact
- ace-pharm.be
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied